Patients were classified into 3 subgroups: HR-positive/HER2-negative (5/20, 25%), HER2-positive (6/20, 30%), and HR-negative/HER2-negative (9/20, 45%), according to breast cancer subtype classification (Table 2). This evidence concerns the gene ERBB2 and breast carcinoma.